Non-Insulin Therapies for Diabetes Market, by Drug Class (Biguanides, Sulfonylureas Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, GLP-1 Analogs, and Sodium-glucose co-transporter-2 (SGLT2) inhibitors), by Route of Administration (Oral and Injectable), by Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022-2028
Select a License Type that Suits your Business Needs
Excel Databook
US$ 2,200
Two thousand two hundred dollars
Single User License
( Full Report )
US$ 4,500
US$ 2,500
Two thousand five hundred dollars
Frequently purchased
Multi User License
( Full Report )
US$ 7,000
US$ 3,850
Three thousand five hundred dollars
Corporate User License
( Full Report )
US$ 10,000
US$ 6,000
Seven thousand five hundred dollars
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
AUS : 
INDIA :